Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUXAM8)

Drug Name

4D-110 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Choroideremia	9B61	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Rab proteins geranylgeranyltransferase component A 1 (CHM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BIIB111	DMQCE1T	Choroideremia	9B61	Phase 3	[3]
SPK-7001	DMEVGI9	Choroidal dystrophy	9B61	Phase 1/2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Rab proteins geranylgeranyltransferase component A 1 (CHM)	TTOA18V	RAE1_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04483440) Phase 1 Open-Label, Dose-Escalation Study of the Safety, Tolerability and Preliminary Efficacy of Intravitreal 4D-110 in Patients With Choroideremia. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of 4D Molecular Therapeutics
3	ClinicalTrials.gov (NCT03496012) A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1). U.S.National Institutes of Health.
4	Clinical pipeline report, company report or official report of Spark Therapeutics.